Article Text

Download PDFPDF

Authors' response
  1. Nicola Principi,
  2. Susanna Esposito
  1. Department of Maternal and Pediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
  1. Correspondence to Professor Nicola Principi, Department of Maternal and Pediatric Sciences, Università degli Studi di Milano, Fondazione IRCCS “Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena”, Via Commenda 9, 20122 Milano, Italy; nicola.principi{at}

Statistics from

In their letter, Thomas and Spencer1 claim that our assertion that Staphylococcus aureus is the most important cause of necrotising pneumonia2 is wrong on the basis of the most recent evidence and that Streptococcus pneumoniae is currently the major cause.1 However, although the studies cited by them document an increase in the incidence of necrotising pneumococcal pneumonia,1 we still believe that S aureus is the most important pathogen clinically and therapeutically.

It has recently been found that the incidence of complicated pneumonia in children is increasing and that there is a concurrent increase in the incidence of community-associated methicillin-resistant S aureus (CA-MRSA) infections.3–5 The emergence of CA-MRSA was initially reported in the USA and in subjects with skin infections, but paediatric necrotising pneumonia due to S aureus has been reported in healthy subjects of different ages and patients with underlying diseases such as cystic fibrosis.4 ,5 A high level of suspicion is required in patients with severe community-acquired pneumonia, and CA-MRSA needs to be considered early in its differential diagnosis because it can lead to rapid deterioration and death unless it is appropriately and immediately treated.

Moreover, the specific antimicrobial treatment of CA-MRSA is different from that using the traditional antimicrobial agents currently prescribed for community-acquired pneumonia. Antimicrobial agents that specifically inhibit exotoxin production, such as clindamycin and linezolid, should be preferred.6

Finally, no prophylaxis against CA-MRSA is yet available. On the contrary, necrotising pneumonia due to S pneumoniae is mainly due to serotype 3 and, in a minority of cases, serotypes 1 and 19A.2 All of these are included in the 13-valent pneumococcal conjugate vaccine that has been recently licensed and included in the immunisation schedules approved for children in most industrialised countries.7 This means that the incidence of infections due to S pneumoniae may be significantly reduced in the future, whereas those associated with CA-MRSA can only remain stable or proportionally increase.



  • Linked article 201308.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles